<DOC>
	<DOCNO>NCT00003012</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy regimen effective follow surgery breast cancer . PURPOSE : Randomized phase III trial study effectiveness combination chemotherapy consist cyclophosphamide , methotrexate , fluorouracil without epirubicin treat woman early stage breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Following Surgery Treating Women With Early Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect 4 course epirubicin follow 4 course cyclophosphamide/methotrexate/fluorouracil ( CMF ) versus 8 course CMF adjuvant chemotherapy woman node positive early breast cancer , measure overall event free survival date randomization . II . Compare effect 4 course epirubicin follow 4 course CMF 8 course CMF adjuvant chemotherapy patient , measure acute chronic toxicity . III . Compare effect 4 course epirubicin follow 4 course CMF versus 8 course CMF adjuvant chemotherapy patient , measure quality life . OUTLINE : This randomize , multicenter study . Patients randomize 2 treatment arm within 4 week surgery . Treatment begin within 6 week surgery . One treatment arm receive 8 course cyclophosphamide/methotrexate/fluorouracil ( CMF ) give intravenously ( IV ) every 3 week . The arm receive 4 course epirubicin follow 4 course CMF give IV every 3 week . Patients follow annually 10 year . PROJECTED ACCRUAL : A total 1,000 patient accrue 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , early stage , unilateral invasive breast cancer TNM stag T0 T3 , N01 , M0 , i.e. , Histologically proven axillary node metastasis OR Lymph node negative Not locally advanced If supraclavicular node enlarge suspicious metastasis , negative biopsy supraclavicular node metastasis require No evidence metastases clinically routine stag investigation No past history pure situ carcinoma either breast Primary tumor completely excise PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Performance status : Not specify Hematopoietic : Neutrophil count great 2,000/mm3 Platelet count great 100,000/mm3 No evidence sepsis Hepatic : Adequate hepatic function Bilirubin normal AST/ALT normal Renal : Adequate renal function Creatinine le 1.2 mg/dL Cardiovascular : No clinically significant cardiovascular disease Other : No prior concurrent malignancy except adequately treat basal squamous cell carcinoma skin situ carcinoma cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior tamoxifen allow Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>